Skip to content


The seminar held at AstraZeneca forms part of a Swedish Research Institute (RISE) pilot on the ATMP field in Sweden.

Dr Daniel C Smith, Chief Scientific Officer Cobra Biologics, has been invited to present an overview of Cobra's capabilities in the ATMP field and provide an update on the company's 165mSEK gene therapy manufacturing operations expansion plans.

Arrange to meet with Daniel Smith and Magnus Gustafsson, Business and Corporate Development Director Cobra Biologics, in Gothenburg using the simple form below.

Arrange your meeting

Fields marked * are required

Arrange your meeting

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.